Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24253400 | 0.84 | KCNA3 (0.41) | GRM2KCNA3GSK3BDYRK1AKDM5A | |
| SCHEMBL12911102 | 0.81 | P2RX7 (0.42) | GRM2KCNA3MAPTGSK3BDYRK1A | |
| SCHEMBL22231667 | 0.81 | KCNA3 (0.39) | GRM2KCNA3GSK3BDYRK1AKDM5A | |
| SCHEMBL1662858 | 0.79 | BAZ2B (0.46) | GRM2KCNA3CNR1BRD4GSK3B | |
| SCHEMBL13925852 | 0.79 | GRM2 (0.48) | GRM2KCNA3SMYD3 | |
| SCHEMBL17518681 | 0.78 | GSK3B (0.42) | GRM2KCNA3GSK3BDYRK1AKDM5A | |
| SCHEMBL26605437 | 0.78 | GSK3B (0.40) | GRM2KCNA3GSK3BDYRK1AKDM5A | |
| SCHEMBL1829985 | 0.77 | L3MBTL1 (0.51) | GRM2L3MBTL1 | |
| SCHEMBL27284572 | 0.77 | KCNA3 (0.46) | GRM2KCNA3CNR1 | |
| SCHEMBL20438538 | 0.76 | KDM5A (0.40) | GRM2GSK3BDYRK1AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | GRM2 52/4885KCNA3 373/4885CNR1 30/4885 |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | GRM2 52/4885KCNA3 373/4885CNR1 30/4885 |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | GRM2 52/4885KCNA3 373/4885CNR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.